Praxis Precision Medicines has received Breakthrough Therapy Designation (BTD) from the FDA for relutrigine, a sodium channel modulator intended for pediatric treatment of SCN2A and SCN8A ...
Praxis Precision Medicines said federal regulators have granted their breakthrough therapy designation, or BTD, to its seizure treatment, relutrigine. The clinical-stage biopharmaceutical company said ...
The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The ...
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stock experienced a volatile trading session on Monday, after the company announced positive topline results from its Phase 2 RADIANT study evaluating ...
LAS VEGAS (KLAS) — A possible “molecular breakthrough” is happening in the Las Vegas valley. A group of UNLV students and neuroscientists has found a way to take something as common as caraway, also ...
Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure freedom New X-TOLE OLE data analysis supports the ability ...
Seizures can happen for many reasons, and there are different types of seizures.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results